References
- Al Khouri Fallouh N., Roblot-Treupel L., Fessi H., Devissaguet J. P., Puisieux F. Development of a new process for the manufacture of polyisobutylcyanoacrylate nanocapsules. Int. J. Pharm. (1986); 28: 125–132
- Aprahamian M., Damgé C., Humbert W., Balboni G., Andrieu V., Devissaguet J. P. Le vecteurs colloidaux polymeriques (nanocapsules) frainchissent-ils la barrière intestinale?. Proc. Int. Conf. Pharm. Tech. (1986); 4: 175–182
- Andrieu V., Dubrasquet M., Fessi H., Devissaguet J. P. Etude pharmacocinétique, biopharmaceutique et de tolérance digestive de dispersions colloidales d'lndométhacine. APGl (1986); 3: 166–174
- Couvreur P. Polyalkylcyanoacrylates as colloidal drug carriers. CRC Critical Reviews in Therapeutic Drug Carrier Systems (1988); 5: 1–20
- Couvreur P., Kante B., Roland M., Guiot P., Bauduin P., Speiser P. Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties. J. Pharm. Pharmacol. (1979); 31: 331–332
- Damgé C., Michel C., Aprahamian M., Couvreur P. New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes (1988); 37: 246–251
- Fishman P. H., Brady R. O. Distribution and function of gangliosides. Science (1976); 194: 906–915
- Lenaerts V., Negelkerke J. F., Van Berkel T. J.C., Couvreur P., Grislain L., Roland M., Speiser P. In vivo uptake of polyisobutylcyanoacrylate nanoparticles by rat liver Kupffer, endothelial and parenchymal cells. J. Pharm. Sci. (1984); 73: 980–983
- Lenaerts V., Couvreur P., Christiaens-Leyh D., Joins E., Rollman B., Speiser P. Identification and study of degradation way for poly(isobutylcyanoacrylate) nanoparticles. Biomaterials (1984); 5: 65–68
- Leeden R. W. Biology of gangliosides: neuritogenic and neuronotrophic properties. J. Neurosci. Res. (1984); 12: 147–159
- Massarotti M. Ganglioside therapy of peripheral neuropathies: a review of clinical literature. Ganglioside and Neuronal Plasticity, G. Tettamanti, R. W. Ledeen, K. Sandhoff, Y. Nagan, G. Toffano. Springer Verlag. (1986); 11465–479
- Michel C., Couvreur P., Vranckx H., Damgé C., Pnisieux F., Balschmidt P. Composition pharmaceutiques contenant de l'insuline pour utilisation dans le traitement du diabète. 1990
- Muller R. H., Lherm C., Herbort J., Blunk T., Couvreur P. Alkylcyanoacrylate drug carrier 1. Physicochemical characterization of nanoparticles with different alkyl chain length. Int. J. Pharm., in press
- Polato L., Benedetti L., Marcolongo G., Callegaro L. (1990) Development and in vitro evaluation of an oral formulation for monoganglioside GM1. Proc. of the 4th Int. Conf. on Polymers in Medicine: Biomedical and Pharmaceutical Applications. September 11–13, 1990. Riva del Garda, Italy
- Svennerholm L. Ganglioside designation. Adv. Exp. Med. Biol. (1980); 125: 11–19
- Verdun C., Couvreur P., Vranckx H., Lenaearts V., Roland M. Development of a nanoparticle controlled release formulation for human use. J. Controlled Release (1986); 3: 205–210